364 related articles for article (PubMed ID: 8270977)
1. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
Bailey HH; Ripple G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Mahvi D; Schink J; Pomplun M; Mulcahy RT; Wilding G
J Natl Cancer Inst; 1997 Dec; 89(23):1789-96. PubMed ID: 9392620
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Gallo JM; Brennan J; Hamilton TC; Halbherr T; Laub PB; Ozols RF; O'Dwyer PJ
Cancer Res; 1995 Oct; 55(20):4507-11. PubMed ID: 7553617
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
Anderson CP; Matthay KK; Perentesis JP; Neglia JP; Bailey HH; Villablanca JG; Groshen S; Hasenauer B; Maris JM; Seeger RC; Reynolds CP
Pediatr Blood Cancer; 2015 Oct; 62(10):1739-46. PubMed ID: 26153194
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
[TBL] [Abstract][Full Text] [Related]
7. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment.
Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ
Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
9. L-S,R-buthionine sulfoximine: historical development and clinical issues.
Bailey HH
Chem Biol Interact; 1998 Apr; 111-112():239-54. PubMed ID: 9679558
[TBL] [Abstract][Full Text] [Related]
10. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
11. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
12. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
O'Dwyer PJ; Hamilton TC; Young RC; LaCreta FP; Carp N; Tew KD; Padavic K; Comis RL; Ozols RF
J Natl Cancer Inst; 1992 Feb; 84(4):264-7. PubMed ID: 1734088
[No Abstract] [Full Text] [Related]
13. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
14. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
Lacreta FP; Brennan JM; Hamilton TC; Ozols RF; O'Dwyer PJ
Drug Metab Dispos; 1994; 22(6):835-42. PubMed ID: 7895599
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the cytostatic effect of melphalan on colorectal cancer hepatic metastases by infusion of buthionine sulfoximine (BSO) in the rat: enhanced tumor glutathione depletion by infusion of BSO in the hepatic artery.
Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
Cancer Chemother Pharmacol; 1999; 44(2):111-6. PubMed ID: 10412944
[TBL] [Abstract][Full Text] [Related]
17. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
Prezioso JA; FitzGerald GB; Wick MM
J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
[TBL] [Abstract][Full Text] [Related]
18. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
Shrieve DC; Harris JW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
[TBL] [Abstract][Full Text] [Related]
19. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM
Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells.
Dorr RT; Liddil JD; Soble MJ
Invest New Drugs; 1986; 4(4):305-13. PubMed ID: 3583642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]